Cell & Gene Therapy · Health Care
Adapt Immune news and milestones
Adapt Immune: 13 headlines on record, 0 headlines in the last 90 days. Its story counts 10 milestones.
Data updated Nov 17, 2026 · Back to the company report
13Headlines
0In 90 days
10Milestones
Headlines
Nov 17, 20252025
Press release
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") toda…
Oct 20, 20252025
Press release
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today an…
Aug 13, 20252025
Press release
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents 150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-c…
Jul 28, 20252025
News · YahooFinance
A deal with US WorldMeds includes the FDA-approved TCR therapy Tecelra and two clinical-stage cancer medicines.
Jul 28, 20252025
Press release
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration wi…
May 13, 20252025
Press release
TECELRA launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales…
May 7, 20252025
Press release
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid t…
Mar 20, 20252025
Press release
TECELRA launch momentum accelerating - 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiat…
Mar 12, 20252025
Press release
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of soli…
Jan 31, 20252025
Press release
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatm…
Jan 13, 20252025
Press release
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune A…
Oct 8, 20242024
News · The Philadelphia Inquirer, LLC
The first patient blood samples, just weeks away, will open a new chapter in medicine's ongoing search for a therapy that converts the body's own immune system to a cancer-killin…
Aug 3, 20242024
News · MedCity News
The FDA approved Adaptimmune Therapeutics' Tecelra as a treatment for advanced cases of synovial sarcoma. It's the first engineered cell therapy approved for treating a solid tum…
Sources: the outlets named on each headline, each story once
Milestones
Aug 23, 2014
Apr 7, 2014
Jul 16, 2013
Oct 12, 2012
Jul 10, 2012
Jan 23, 2012
Jul 27, 2011
Jan 21, 2011
Sep 28, 2010
Jun 18, 2010
Each milestone is dated by its source: registers, filings, the press
How to cite
Adapt Immune, News. Alion, Nov 17, 2026. https://alion.io/company/adaptimmune/news
